Drug found in trials to cut vulnerable adults’ risk of hospital admission and death by 79%
The UK drugs watchdog has approved a new Covid treatment after trials found it cut the likelihood of hospital admission and death by 79% in high-risk adults.
The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised Xevudy (sotrovimab), a monoclonal antibody made by GlaxoSmithKline (GSK) and Vir Biotechnology, for people with mild to moderate Covid-19 at high risk of developing severe disease.
Continue reading...from The Guardian https://ift.tt/3DcSMiJ
No comments:
Post a Comment